Skip to content

Dasatinib

Dasatinib (Sprycel) is a tyrosine kinase inhibitor used to treat chronic myeloid leukaemia. This page lists the one formulation available in the catalogue.

Sprycel

Chronic Myeloid Leukaemia

50mg

Dasatinib tablets for chronic myeloid and acute lymphocytic leukaemia. It blocks proteins that drive leukaemia cell growth.

From$129.00/ bottleView

Key points

  • Dasatinib is also used for acute lymphocytic leukaemia, a cancer of the white blood cells that can affect both adults and children.
  • The single listed product is Sprycel 50mg, the only formulation of dasatinib in the catalogue, supplied in a bottle.
  • It works by blocking tyrosine kinase, a protein signal that tells leukaemia cells to grow and multiply.

Common questions about Dasatinib

What is the strength of Dasatinib in this catalogue?

Dasatinib is listed in this catalogue at a single strength of 50mg, sold as Sprycel in a bottle. Bristol-Myers Squibb is the originator company behind this brand, which is used in the treatment of leukaemia.

Who makes Sprycel?

Bristol-Myers Squibb markets Sprycel as the originator brand for dasatinib, a medicine used in the treatment of leukaemia. It is the only formulation of dasatinib currently available in the catalogue.

Further reading